December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

133.55 +2.17 (+1.65%)
Streaming Delayed Price Updated: 9:46 AM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Biotech ETF

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
3 Longevity ETFs to Buy and Hold (and Hold) ↗
The size of the longevity industry could roughly triple in the next decade, and these ETFs may help to provide access to a fast-growing space. 
Via MarketBeat
Topics Artificial Intelligence ETFs
News headline image
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech ↗
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns. 
Via The Motley Fool
Topics ETFs
News headline image
VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost ↗
Expense ratios, yield, and sector breadth set these healthcare ETFs apart—see how their risk profiles and portfolio strategies compare. 
Via The Motley Fool
Topics ETFs
News headline image
2 Ways to Play the Big Pharma Patent Cliff ↗
With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize. 
Via MarketBeat
Topics ETFs Intellectual Property
News headline image
Small Caps Under Siege: Russell 2000 Enters Correction as Yields Surge
The small-cap segment of the U.S. stock market has officially entered correction territory, marking a stark reversal for a sector that many analysts expected to lead the "Great Rotation" of 2026. On... 
Via MarketMinute
Topics Bonds ETFs Economy
News headline image
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but... 
Via The Motley Fool
Topics Derivatives ETFs Regulatory Compliance
News headline image
IBRX Stock Rises Overnight: Retail Bets Anktiva’s NCCN 'Recommended' Tag Will Drive Prescriptions And Insurance Wins ↗
Users highlighted that NCCN inclusion could lead to increased prescribing of Anktiva by oncologists and improved insurance reimbursement. 
Via Stocktwits
Topics ETFs
News headline image
The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE)
Date: March 12, 2026Sector: Biotechnology / NeurologyMarket Cap: ~$4.8 Billion Introduction On March 9, 2026, the neurology sector of the biotechnology market witnessed a seismic shift. Xenon... 
Via Finterra
Topics ETFs Intellectual Property
News headline image
Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest? ↗
Watcher count for PLYX on Stocktwits increased by nearly 50% in a single day. 
Via Stocktwits
Topics ETFs
News headline image
QURE Stock Edges Up After Hours As Analyst Flags Reduced Regulatory Uncertainty Following Prasad’s FDA Exit ↗
Mizuho said that Dr. Vinay Prasad’s exit just days after a highly public dispute with uniQure appeared to signal an administration-level desire to restore greater regulatory flexibility in rare disease... 
Via Stocktwits
News headline image
QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure ↗
H.C. Wainwright stated that the reported departure of a key U.S. Food and Drug Administration official at the end of April bodes well for uniQure. 
Via Stocktwits
Topics Initial Public Offering
News headline image
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 ↗
Wells Fargo upgraded uniQure’s stock to ‘Overweight,’ citing a bullish outlook for its gene therapy following reports that Vinay Prasad will leave the U.S. FDA next month. 
Via Stocktwits
News headline image
IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data ↗
ImmunityBio stated that the application includes additional information requested by the FDA to support its supplemental BLA for papillary disease. 
Via Stocktwits
News headline image
ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns ↗
CFO says company continues to be “strategic and opportunistic” in approach to securing capital needed for late-stage MASH trial. 
Via Stocktwits
News headline image
Why Did CRMD Stock Tumble Over 11% Today? ↗
The company reported mixed Q4 results with a revenue of $128.6 million and earnings per share of $0.16. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Why Did BTAI Stock Surge 20% In Pre-Market Today? ↗
BioXcel announced positive Phase 2 results for evaluating treatment for opioid withdrawal symptoms. 
Via Stocktwits
News headline image
Liquidia Stock Gains Premarket On Q4 Revenue Beat – Investors Are Betting On YUTREPIA Growth ↗
Product revenue from YUTREPIA reached approximately $148.3 million in 2025, including about $90.1 million generated during the fourth quarter alone. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
DAWN Shares Rally On Buyout Speculation But Retail Warns A Deal Might Not Materialise ↗
On Stocktwits, retail sentiment around DAWN stock stayed within the ‘extremely bullish’ territory over the past 24 hours. 
Via Stocktwits
Topics Economy
News headline image
IBRX Stock Drops On Investor Concerns Over Immunotherapy Launch In Saudi Arabia Amid Middle East Tensions But Analyst Sees 20% Upside ↗
Piper Sandler raised the firm's price target on ImmunityBio to $12 from $7 and kept an ‘Overweight’ rating on the shares. 
Via Stocktwits
Topics Intellectual Property
News headline image
Why Did NTLA Stock Jump 10% In Pre-Market Today? ↗
The company announced that the U.S. FDA lifted a clinical hold on its Phase 3 trial of ATTR-CM treatment drug. 
Via Stocktwits
News headline image
Why Did QURE Stock Almost Halve Pre-Market Today? ↗
uniQure said the FDA does not agree that Phase I/II data are sufficient to serve as primary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy, AMT-130. 
Via Stocktwits
News headline image
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction ↗
The company said on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027. 
Via Stocktwits
News headline image
IBRX Stock Rises Pre-Market After ANKTIVA Combo Shows Stronger Bladder Cancer Responses In Phase 2 Trial ↗
The company said it plans to submit a biologics license application by the fourth quarter of 2026. 
Via Stocktwits
News headline image
CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent ↗
The company said it has enrolled patients in its late-stage program ahead of schedule. 
Via Stocktwits
Topics Earnings
News headline image
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ ↗
Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts ↗
According to data from Fiscal AI, Novavax is expected to report a quarterly loss per share of $0.55, higher than the loss of $0.52 reported in the corresponding quarter of 2024. 
Via Stocktwits
Topics Artificial Intelligence Earnings
News headline image
Why Did PVLA Stock Surge 45% In Pre-Market Today? ↗
The biotech company reported statistically significant Phase 3 data for QTORIN gel. 
Via Stocktwits
News headline image
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder ↗
The company applied for approval of the gene therapy in the treatment of Glycogen Storage Disease Type Ia or Von Gierke disease. 
Via Stocktwits
News headline image
ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts ↗
ImmunityBio announced that it has partnered with Biopharma and Cigalah and hopes to launch Anktiva across the broader Middle East and North Africa (MENA) region over time. 
Via Stocktwits
News headline image
ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? ↗
Analysts at H.C. Wainwright hiked their price target for Ardelyx shares to $18 from $10. 
Via Stocktwits
Topics Earnings Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.